Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib
Inflammatory Bowel Diseases · 2023
DOI: 10.1093/ibd/izac063 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Inflammatory Bowel Diseases, 2023. Verfasst von Kevin L Winthrop und 11 weiteren Autor:innen. Beteiligte Einrichtung: Oregon Health & Science University, Portland, Oregon, USA. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Herpes Zoster. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Background
Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We report herpes zoster (HZ) incidence and risk factors in the tofacitinib UC clinical program (up to 7.8 years).
Methods
Proportions and incidence rates (IRs; unique patients with events/100 patient-years) of HZ were evaluated in 4 cohorts: Induction (phase 2 and 3 induction study data), Maintenance (phase 3 maintenance study data), Overall (data from all phase 2, 3, and open-label, long-term extension studies), and Overall plus interim 6-month phase 3b and 4 data. Herpes zoster risk factors were assessed by Cox regression analysis.
Results
In the Induction and Maintenance Cohorts, IRs for HZ (nonserious and serious) were numerically higher with tofacitinib 10 mg twice daily (BID) vs placebo and tofacitinib 10 vs 5 mg BID, respectively. With all tofacitinib doses (5 or 10 mg BID), IRs (95% confidence intervals) for HZ in the Overall and Overall plus phase 3b/4 Cohorts (total exposure, 2814.4 and 2999.7 patient-years, respectively) were 3.38 (2.73-4.15) and 3.30 (2.67-4.04), respectively. In the Overall plus phase 3b/4 Cohort, >90% of HZ were nonserious; >90% were mild/moderate; >90% resolved without discontinuing tofacitinib; 0.6% of patients had multiple HZ events. Herpes zoster IRs were stable when analyzed by 6-month intervals up to >30 months. Herpes zoster risk factors included older age, lower weight, geographic region, and prior tumor necrosis factor inhibitor (TNFi) failure.
Conclusions
Most HZ events were mild/moderate. Herpes zoster IRs remained stable over 7.8 years of exposure. Older age, lower weight, geographic region, and prior TNFi failure were associated with increased HZ risk. ClinicalTrials.gov NCT00787202;NCT01465763;NCT01458951;NCT01458574;NCT01470612;NCT03281304
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oregon Health & Science University, Portland, Oregon, USA.
- Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.
- University of North Carolina, Center for Gastrointestinal Biology and Disease, Chapel Hill, North Carolina, USA.
- Department of Gastroenterology, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.
- Institute of Digestive Disease, Department of Medicine and Therapeutics, LKS Institute of Health Science, Chinese University of Hong Kong, Hong Kong.
- Pfizer Inc, Collegeville, Pennsylvania, USA.
ORCID-Profile: Kevin L Winthrop, Millie D Long
Förderung
- Pfizer
Zitieren
APA
Winthrop, K. L., Vermeire, S., Long, M. D., Panés, J., Ng, S. C., Kulisek, N., Mundayat, R., Lawendy, N., Vranic, I., Modesto, I., Su, C., & Melmed, G. Y. (2023). Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izac063
Vancouver
Winthrop KL, Vermeire S, Long MD, Panés J, Ng SC, Kulisek N, et al. Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. Inflammatory Bowel Diseases. 2023. doi:10.1093/ibd/izac063
BibTeX
@article{Winthrop2023,
author = {Winthrop, Kevin L and Vermeire, Séverine and Long, Millie D and Panés, Julian and Ng, Siew C and Kulisek, Nicole and Mundayat, Rajiv and Lawendy, Nervin and Vranic, Ivana and Modesto, Irene and Su, Chinyu and Melmed, Gil Y},
title = {Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib},
journal = {Inflammatory Bowel Diseases},
year = {2023},
doi = {10.1093/ibd/izac063}
}
EUVIMED